Shipping out mek inhibitor resistance with shp2 inhibitors

Pedro Torres-Ayuso; John Brognard

doi:10.1158/2159-8290.CD-18-0915

Shipping out mek inhibitor resistance with shp2 inhibitors

Pedro Torres-Ayuso, John Brognard

National Institutes of Health

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors prevent adaptive MEK inhibitor resistance; therefore, combining MEK and SHP2 inhibitors represents an exciting new therapeutic approach for the treatment of RAS-driven cancers.

Original language	English
Pages (from-to)	1210-1212
Number of pages	3
Journal	Cancer Discovery
Volume	8
Issue number	10
DOIs	https://doi.org/10.1158/2159-8290.CD-18-0915
State	Published - Oct 2018
Externally published	Yes

Access to Document

10.1158/2159-8290.CD-18-0915

Cite this

@article{d9665e2bf115494bbc189da3fa555d90,

title = "Shipping out mek inhibitor resistance with shp2 inhibitors",

abstract = "RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors prevent adaptive MEK inhibitor resistance; therefore, combining MEK and SHP2 inhibitors represents an exciting new therapeutic approach for the treatment of RAS-driven cancers.",

author = "Pedro Torres-Ayuso and John Brognard",

note = "Publisher Copyright: {\textcopyright}2018 American Association for Cancer Research.",

year = "2018",

month = oct,

doi = "10.1158/2159-8290.CD-18-0915",

language = "English",

volume = "8",

pages = "1210--1212",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "10",

}

TY - JOUR

T1 - Shipping out mek inhibitor resistance with shp2 inhibitors

AU - Torres-Ayuso, Pedro

AU - Brognard, John

PY - 2018/10

Y1 - 2018/10

N2 - RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors prevent adaptive MEK inhibitor resistance; therefore, combining MEK and SHP2 inhibitors represents an exciting new therapeutic approach for the treatment of RAS-driven cancers.

AB - RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors prevent adaptive MEK inhibitor resistance; therefore, combining MEK and SHP2 inhibitors represents an exciting new therapeutic approach for the treatment of RAS-driven cancers.

UR - http://www.scopus.com/inward/record.url?scp=85054399099&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-18-0915

DO - 10.1158/2159-8290.CD-18-0915

M3 - Article

SN - 2159-8274

VL - 8

SP - 1210

EP - 1212

JO - Cancer Discovery

JF - Cancer Discovery

IS - 10

ER -

Shipping out mek inhibitor resistance with shp2 inhibitors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this